参考文献/References:
[1]MAGGIO I, FRANCESCHI E, TOSONI A, et al. Meningioma: not always a benign tumor: a review of advances in the treatment of meningiomas [J]. CNS Oncol, 2021, 10(2): CNS72-CNS87.
[2]LOUIS DN, PERRY A, WESSELING P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary [J]. Neuro Oncol, 2021, 23(8): 1231-1251.
[3]WU Z, YANG SZ, CHEN L. Correlation between expressions of AQP-4 and VEGF and postoperative cerebral edema exacerbation in patients with meningioma [J]. Chin J Clin Neurosurg, 2022, 27(5): 363-365, 369.
吴 珠，杨生长，陈 力. AQP-4、VEGF表达与脑膜瘤术后脑水肿加重的相关性分析[J]. 中国临床神经外科杂志，2022，27（5）：363-365，369.
[4]GOLDBRUNNER R, STAVRINOU P, JENKINSON MD, et al. EANO guideline on the diagnosis and management of meningiomas [J]. Neuro Oncol, 2021, 23(11): 1821-1834.
[5]TOLLEFSEN SE, SOLHEIM O, MJONES P, et al. Meningiomas and somatostatin analogs: a systematic scoping review on current insights and future perspectives [J]. Int J Mol Sci, 2023, 24(5): 4793-4806.
[6]SHARMA S, RANA R, PRAKASH P, et al. Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors [J]. Mol Cell Biochem, 2023, 479(1): 127-170.
[7]CHAMBERLAIN M C. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma [J]. J Neurooncol, 2012, 107 (2): 315-321.
[8]BRASTIANOS PK, KIM AE, GIOBBIE-HURDER A, et al. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas [J]. Nat Commun, 2022, 13(1): 1325-1331.
[9]BI WL, NAYAK L, MEREDITH DM, et al. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase Ⅱ trial results [J]. Neuro Oncol, 2022, 24 (1): 101-113.
[10]BUERKI RA, HORBINSKI CM, KRUSER T, et al. An overview of meningiomas [J]. Future Oncol, 2018, 14(21): 2161-2177.
[11]PREUSSER M, SILVANI A, LE RHUN E, et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase Ⅱ study of the EORTC Brain Tumor Group (EORTC-1320-BTG) [J]. Neuro Oncol, 2022, 24(5): 755-767.
[12]WU W, ZHOU Y, WANG Y, et al. Clinical significance of somatostatin receptor (SSTR) 2 in meningioma [J]. Front Oncol, 2020, 10: 1633-1644.
[13]GRAILLON T, SANSON M, CAMPELLO C, et al. Everolimus and octreotide for patients with recurrent meningioma: results from the Phase Ⅱ CEVOREM Trial [J]. Clin Cancer Res, 2020, 26(3): 552-557.
[14]DAS A, ALSHAREEF M, HENDERSON F, et al. Ganoderic acid A/ DM-induced NDRG2 over-expression suppresses high-grade meningioma growth [J]. Clin Transl Oncol, 2020, 22: 1138-1145.
[15]YOUNG JS, KIDWELL RL, ZHENG A, et al. CDK 4/6 inhibitors for the treatment of meningioma [J]. Front Oncol, 2022, 12: 931371.
[16]ZHANG B, YUE HY. CDK4/6 inhibitors-based combinational therapy for human cancers [J]. Cancer Res Prevent Treat, 2019, 46(1): 72-75.
张百红，岳红云. CDK4/6抑制剂的联合治疗模式[J]. 肿瘤防治研究，2019，46（1）：72-75.
[17]VON ACHENBACH C, LE RHUN E, SAHM F, et al. Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02 [J]. Transl Oncol, 2020, 13(12): 100852.
[18]XUE Z, LUI VWY, LI Y, et al. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma [J]. J Exp Clin Cancer Res, 2020, 39(1): 262-285.
[19]MAIR MJ, BERGHOFF AS, BRASTIANOS PK, et al. Emerging systemic treatment options in meningioma [J]. J Neurooncol, 2023, 161 (2): 245-258.
[20]PREUSSER M, BRASTIANOS PK, MAWRIN C. Advances in meningioma genetics: novel therapeutic opportunities [J]. Nat Rev Neurol, 2018, 14(2): 106-115.
[21]SAGERS JE, BEAUCHAMP RL, ZHANG Y, et al. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma [J]. Sci Rep, 2020, 10(1): 4211-4220.
[22]CARDONA AF, RUIZ-PATIO A, ZATARAIN-BARRN ZL, et al. Systemic management of malignant meningiomas: a comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib [J]. PLoS One, 2019, 14 (6): e0217340.
[23]WALDT N, KESSELER C, FALA P, et al. Crispr/Cas-based modeling of NF2 loss in meningioma cells [J]. J Neurosci Methods, 2021, 356: 109141.
[24]MILLWARD CP, ARMSTRONG TS, BARRINGTON H, et al. Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings [J]. BMJ Open, 2022, 12(5): e057384.
[25]VON SPRECKELSEN N, WALDT N, POETSCHKE R, et al. KLF4K409Q-mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment [J]. Acta Neuropathol Commun, 2020, 8(1): 41-51.
[26]OKANO A, MIYAWAKI S, TERANISHI Y, et al. Advances in molecular biological and translational studies in World Health Organization grades 2 and 3 meningiomas: a literature review [J]. Neurol Med Chir (Tokyo), 2022, 62(8): 347-360.
[27]FINDAKLY S, CHOUDHURY A, DAGGUBATI V, et al. Meningioma cells express primary cilia but do not transduce ciliary Hedgehog signals [J]. Acta Neuropathol Commun, 2020, 8(1): 114-120.
[28]KALEY TJ, WEN P, SCHIFF D, et al. Phase Ⅱ trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma [J]. Neuro Oncol, 2015, 17(1): 116-121.
[29]GARZON-MUVDI T, BAILEY DD, PERNIK M N, et al. Basis for immunotherapy for treatment of meningiomas [J]. Front Neurol, 2020, 11: 945-955.
[30]BERGHOFF AS, KRESL P, RAJKY O, et al. Analysis of the inflammatory tumor microenvironment in meningeal neoplasms [J]. Clin Neuropathol, 2020, 39(6): 256-262.
[31]YEUNG J, YAGHOOBI V, MIYAGISHIMA D, et al. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas [J]. Neuro Oncol, 2021, 23(11): 1922-1935.
[32]CAPPER D, JONES DTW, SILL M, et al. DNA methylation-based classification of central nervous system tumours [J]. Nature, 2018, 555(7697): 469-474.
[33]BERGHOFF AS, HIELSCHER T, RICKEN G, et al. Prognostic impact of genetic alterations and methylation classes in meningioma [J]. Brain Pathol, 2022, 32(2): e12970-e12980.
相似文献/References:
[1]李春坡 郑 军 李海元 边 涛 韩安国.侧脑室三角区小型脑膜瘤的显微外科治疗[J].中国临床神经外科杂志,2015,(11):694.[doi:10.13798/j.issn.1009-153X.2015.11.018]
[2]王林风 郑华山 操 廉.中央沟区矢状窦旁脑膜瘤的显微手术治疗（附25例报告）[J].中国临床神经外科杂志,2016,(07):431.[doi:10.13798/j.issn.1009-153X.2016.07.014]
[3]邓学云 刘 毅 范润金 刘丽华 夏祥国.E-cadherin与脑膜瘤分级及瘤周水肿的关系[J].中国临床神经外科杂志,2016,(04):213.[doi:10.13798/j.issn.1009-153X.2016.04.007]
DENG Xue-yun,LIU Yi,FAN Run-jin,et al.Relationship of E-cadherin with the pathological grade of meningioma and peritumoral brain edema in patients with meningioma[J].,2016,(03):213.[doi:10.13798/j.issn.1009-153X.2016.04.007]
[4]马 磊 张海红 郭 康 孙树凯 张 亮 贾 栋.神经导航辅助下手术治疗侧脑室脑膜瘤1例[J].中国临床神经外科杂志,2016,(04):255.[doi:10.13798/j.issn.1009-153X.2016.04.023]
[5]王 一 崔焕喜 林令超 孙思辉 李绍山 周庆九 刘 波 柳 琛.侧脑室三角区脑膜瘤的显微手术治疗[J].中国临床神经外科杂志,2016,(03):161.[doi:10.13798/j.issn.1009-153X.2016.03.010]
WANG Yi,CUI Huan-xi,LIN Ling-chao,et al.Microsurgery for meningiomas in the trigones of lateral ventricles (report of 47 cases)[J].,2016,(03):161.[doi:10.13798/j.issn.1009-153X.2016.03.010]
[6]王 鹏 综述 王 勇 审校.岩斜区脑膜瘤的手术入路[J].中国临床神经外科杂志,2016,(02):120.[doi:10.13798/j.issn.1009-153X.2016.02.024]
[7]漆松涛 刘 忆.关于WHO2007年版脑膜瘤病理分类一些问题的商榷[J].中国临床神经外科杂志,2016,(02):125.[doi:10.13798/j.issn.1009-153X.2016.02.026]
[8]李登辉 程 荆 李志强.镰旁脑膜瘤术后并发格林巴利综合征1例[J].中国临床神经外科杂志,2016,(02):72.[doi:10.13798/j.issn.1009-153X.2016.02.003]
[9]唐 铸 桂 铮 李延良 赵建伍 余天垒 张鹏飞 赵立文 于耀宇.药物PAS与支架置入术治疗症状性颈动脉重度狭窄的近期疗效对比分析[J].中国临床神经外科杂志,2015,(12):727.[doi:10.13798/j.issn.1009-153X.2015.12.007]
TANG Zhu,GUI Zheng,LI Yan-liang,et al.Comparison of clinical effect of intensive therapy with PAS on severe symptomatic carotid artery stenosis with that of carotid artery stenting[J].,2015,(03):727.[doi:10.13798/j.issn.1009-153X.2015.12.007]
[10]肖宗宇 陈晓娟 裴 杰 贺瑛福 许常林 马进海.超声吸引器在脑膜瘤手术切除中的应用[J].中国临床神经外科杂志,2015,(10):626.[doi:10.13798/j.issn.1009-153X.2015.10.016]